TransMedics Group Inc (NAS:TMDX)
$ 59.79 -1.23 (-2.02%) Market Cap: 2.01 Bil Enterprise Value: 2.23 Bil PE Ratio: 63.61 PB Ratio: 9.55 GF Score: 70/100

Transmedics Group Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 08:15PM GMT
Release Date Price: $23.95 (+0.46%)
David Ryan Lewis
Morgan Stanley, Research Division - MD

Let's get going here as we kind of wrap up our first day at the health care conference. My name is David Lewis, medical device analyst here at Morgan Stanley. It's my pleasure to have with us here several members of -- 2 members of the TransMedics management team, Waleed Hassanein and Stephen Gordon, CEO and CFO, respectively.

Questions & Answers

David Ryan Lewis
Morgan Stanley, Research Division - MD

We're going to jump straight into Q&A. But I thought, Waleed, just given some of the recent IPO, it'd be kind of helpful just to help people frame sort of the broader opportunity for the business. Maybe just quickly tell us or capsulate, what is the problem with today's organ transplantation, sort of what is the problem that OCS is trying to solve?

Waleed H. Hassanein
TransMedics Group, Inc. - Founder, CEO, President & Director

Sure. First, thank you, David, for inviting us to the conference. At a high level, I mean, we're very excited about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot